Alligator Bioscience AB
STO:ATORX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Alligator Bioscience AB
Cash & Cash Equivalents
Alligator Bioscience AB
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Alligator Bioscience AB
STO:ATORX
|
Cash & Cash Equivalents
kr62.2m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
|
Biogaia AB
STO:BIOG B
|
Cash & Cash Equivalents
kr801.3m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
|
Bonesupport Holding AB
STO:BONEX
|
Cash & Cash Equivalents
kr455.3m
|
CAGR 3-Years
34%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Vitrolife AB
STO:VITR
|
Cash & Cash Equivalents
kr886m
|
CAGR 3-Years
13%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
16%
|
|
|
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
|
Cash & Cash Equivalents
kr1B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
21%
|
CAGR 10-Years
1%
|
|
|
BioArctic AB
STO:BIOA B
|
Cash & Cash Equivalents
kr1B
|
CAGR 3-Years
9%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
Alligator Bioscience AB
Glance View
Alligator Bioscience AB is a biotech company, which engages in the development of innovative antibody-based medicines for immunotherapy of cancer. The company is headquartered in Lund, Skane and currently employs 46 full-time employees. The company went IPO on 2016-11-23. The firm specializes in the development of tumor-targeted immunotherapies, in particular agonist mono- and bispecific antibodies, and is active in the early stages of drug development, from concept to phase II clinical trials. Alligator’s pipeline includes the two key assets mitazalimab, a CD40 agonist, and ATOR-1017, a 4-1BB agonist. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its technology platform, Neo-X-Prime, with MacroGenics Inc. and drug candidates based on the RUBY bispecific platform with Orion Corporation. Its licensed programs include AC101, in phase II development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc. The firm operates domestically.
See Also
What is Alligator Bioscience AB's Cash & Cash Equivalents?
Cash & Cash Equivalents
62.2m
SEK
Based on the financial report for Dec 31, 2025, Alligator Bioscience AB's Cash & Cash Equivalents amounts to 62.2m SEK.
What is Alligator Bioscience AB's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
-10%
Over the last year, the Cash & Cash Equivalents growth was -3%. The average annual Cash & Cash Equivalents growth rates for Alligator Bioscience AB have been -14% over the past three years , -10% over the past five years .
